Komori
Treasury shares4547KISSEI PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Status of Share Repurchases

No treasury shares were repurchased from 1 June 2026 through 30 June 2026, and both the number of shares acquired and the total acquisition cost were ¥0. The authorized repurchase capacity remains available.

Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
0
yen
Wording
Definitive
How definitive the wording is.

Progress against acquisition limit

Market purchases on the Tokyo Stock Exchange under a discretionary trading agreement for the acquisition of treasury shares

Resolved 11 May 2026 / Acquisition period 12 May 2026 to 31 December 2026

0.0%
Cumulative utilization rate
Limit1,300,000 株 remaining
Number of Shares1,300,000 shares (maximum)
0.0%
Cumulative utilization rate
Limit6,000,000,000 円 remaining
Amount¥6,000,000,000 (maximum)

決議した枠は、まだ手つかずです。

Number of Shares
Limit1,300,000 shares (maximum)
Cumulative total0 shares (as of 30 June 2026)
Current0 shares
Amount
Limit¥6,000,000,000 (maximum)
Cumulative total¥0 (as of 30 June 2026)
Current¥0
Percentage of total issued shares3.14%

消化率と残りは、会社が示した累計・今回と上限から算出しています。進捗率=上限に対してどこまで使ったかの割合です。

Progress against acquisition limit
ItemDetails
Total number of shares acquired in this transaction0 shares
Total current acquisition price¥0
Acquisition date/acquisition period1 June 2026–30 June 2026 (based on contract dates)
Method of acquisitionMarket purchases on the Tokyo Stock Exchange under a discretionary trading agreement for the acquisition of treasury shares
Cumulative number of shares acquired0 shares (as of 30 June 2026)
Cumulative acquisition cost¥0 (as of 30 June 2026)
Resolution date11 May 2026
Maximum number of shares to be acquired1,300,000 shares (maximum)
Total acquisition price¥6,000,000,000 (maximum)
Acquisition period under the resolution12 May 2026 to 31 December 2026
Percentage of total issued shares3.14%
Items this document does not state (2)
Whether acquisition has been completedAverage Acquisition Price

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The document does not restate the reason for the repurchases.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Status of Share Repurchases | KISSEI PHARMACEUTICAL CO.,LTD. (4547) timely disclosure | Komori